As individuals with obesity have an increased risk of cardiovascular disease, which is reduced after RYGB, one could speculate whether the reduction in circulating levels of Lp(a) partly explains the beneficial effects of RYGB on cardiovascular disease risk is at least partly explained by the reduction in circulating levels of Lp(a). The gene discussed is LPA; the disease is Obesity.